Search Results

You are looking at 131 - 140 of 201 items for :

  • "lymph node dissection" x
  • Refine by Access: All x
Clear All
Full access

Presenters: Meena S. Moran and A. Marilyn Leitch

avoidance of axillary lymph node dissection (ALND) in many patients. This recommendation is largely based on findings from ACOSOG Z0011 and SINODAR-ONE, in which patients with clinical T1/T2N0 disease with up to 2 positive sentinel nodes fared equally well

Full access

Michael A. Cilento, Nicola K. Poplawski, Sellvakumaram Paramasivam, David M. Thomas, and Ganessan Kichenadasse

omental caking. CA-125 serum tumor marker at time of presentation was elevated at 1,155 kU/L (normal range, <35 kU/L). The patient underwent primary surgery with radical hysterectomy, bilateral salpingo-oophorectomy, lymph node dissection, and removal of

Full access

Michelle C. Nguyen, Manisha H. Shah, David A. Liebner, Floor J. Backes, John Phay, and Lawrence A. Shirley

-oophorectomy and pelvic and periaortic lymph node dissection for stage III uterine carcinosarcoma in March 2016. She completed 6 cycles of carboplatin and paclitaxel therapy and 4,860 cGy of RT to the pelvic and aortic nodes. She later developed subcutaneous

Full access

Ashwin Shinde, Richard Li, Arya Amini, Yi-Jen Chen, Mihaela Cristea, Wenge Wang, Mark Wakabyashi, Ernest Han, Catheryn Yashar, Kevin Albuquerque, Sushil Beriwal, and Scott Glaser

coding for vulvar cancer regarding whether pelvic lymph nodes are defined as regional or nonregional, and therefore we omitted distinction between inguinal and pelvic lymph node dissection in the setting of regional lymph node evaluation. Treatment

Full access

Aysegul A. Sahin, Timothy D. Gilligan, and Jimmy J. Caudell

with retroperitoneal lymph node dissection only? Which patients with stage II and III disease will need to undergo resection of residual masses after chemotherapy?” he continued. Dr. Gilligan explained that the 8th edition has made some changes, but

Full access

James Mohler, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony D'Amico, James A. Eastham, Charles A. Enke, Daniel George, Eric Mark Horwitz, Robert P. Huben, Philip Kantoff, Mark Kawachi, Michael Kuettel, Paul H. Lange, Gary MacVicar, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Bruce J. Roth, Dennis C. Shrieve, Matthew R. Smith, Sandy Srinivas, Przemyslaw Twardowski, and Patrick C. Walsh

decision-making for men contemplating active surveillance, 12 radical prostatectomy, 13 – 15 neurovascular bundle preservation, 16 – 18 or omission of pelvic lymph node dissection (PLND) during radical prostatectomy, 19 brachytherapy, 13 , 20 , 21 or

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, and Richard Zellars

pregnant during breast cancer treatment (see page 160). Locoregional Treatment Several randomized trials document that mastectomy with axillary lymph node dissection is equivalent to breast-conserving therapy with lumpectomy, axillary dissection

Full access

Mathias Kvist Mejdahl, Birgitte Goldschmidt Mertz, Pernille Envold Bidstrup, and Kenneth Geving Andersen

, 35 receiving surgery with mastectomy or breast-conserving surgery (BCS), and sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) of levels I through II. Adjuvant treatment was according to risk profile, with chemotherapy

Full access

David J. Worhunsky, Yifei Ma, Yulia Zak, George A. Poultsides, Jeffrey A. Norton, Kim F. Rhoads, and Brendan C. Visser

Although multiple quality indicators have been studied for the management of gastric cancer, notably surgical technique and the extent of lymph node dissection, 12 – 14 limited data exist regarding implementation and effectiveness of clinical guidelines

Full access

Daphne Y. Lichtensztajn, John T. Leppert, James D. Brooks, Sumit A. Shah, Weiva Sieh, Benjamin I. Chung, Scarlett L. Gomez, and Iona Cheng

therapy (ADT), RT with brachytherapy with or without 2 to 3 years of ADT, or radical prostatectomy with pelvic lymph node dissection as initial treatment of all high-risk localized PCa, barring contraindications. 2 Despite these recommendations